Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:AXON - Axovant Sciences Stock Price, Forecast & News

Today's Range N/A
50-Day Range
$1.22
MA: $3.16
$5.94
52-Week Range N/A
Volume351,407 shs
Average Volume1.45 million shs
Market Capitalization$651.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.19 per share

Profitability

Net Income$-221,570,000.00

Miscellaneous

EmployeesN/A
Market Cap$651.75 million
Next Earnings DateN/A
OptionableOptionable

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


I call it my "Dividend Map", and I'll show you exactly where to find the safest companies that pay the highest yields. (HINT: Texas has 6 of these companies sending huge payouts that average 77%!). I'm willing to send you my Map... but only if you

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) issued its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.27). View Axovant Sciences' Earnings History.

What price target have analysts set for AXON?

1 analysts have issued twelve-month target prices for Axovant Sciences' shares. Their forecasts range from $32.00 to $32.00. On average, they expect Axovant Sciences' stock price to reach $32.00 in the next twelve months. View Analyst Price Targets for Axovant Sciences.

What is the consensus analysts' recommendation for Axovant Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Sciences.

Has Axovant Sciences been receiving favorable news coverage?

News headlines about AXON stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axovant Sciences earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Axovant Sciences.

Who are some of Axovant Sciences' key competitors?

What other stocks do shareholders of Axovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Canopy Growth (CGC), Immunomedics (IMMU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD) and Ocular Therapeutix (OCUL).

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
  • Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 58)
  • Dr. David T. Hung, Scientific Advisor of Group (Age 61)
  • Dr. Fraser Wright, Chief Technology Officer

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $0.00. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. View Additional Information About Axovant Sciences.

What is Axovant Sciences' official website?

The official website for Axovant Sciences is http://www.axovant.com/.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  389 (Vote Underperform)
Total Votes:  756
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel